223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy

Area of Science:

• Oncology
• Radiopharmaceutical Therapy
• Bone Cancer Research

Background:

• Bone-seeking radiopharmaceuticals target osteosarcoma due to its bone-forming nature.
• Osteosarcoma is a primary bone cancer often requiring innovative treatment strategies.

Purpose of the Study:

• To report the first use of radium-223 (an alpha-emitter) in combination therapy for metastatic osteoblastic osteosarcoma.
• To evaluate the efficacy and safety of radium-223 combined with other agents in osteosarcoma patients.

Main Methods:

• Fifteen patients with metastatic osteoblastic osteosarcoma received monthly radium-223 infusions.
• Combination therapies included agents targeting skeletal complications, VEGF activity, alkylating agents, and chemotherapy.
• Concurrent or sequential radiation therapy, including stereotactic body radiotherapy (SBRT), was administered to 11 patients.

Main Results:

• The median number of radium-223 infusions was three, with an average time to progression of 4.3 months.
• Patients receiving radium-223 combined with radiation therapy (SBRT and/or RT) had a median overall survival of 13.5 months.
• Patients without radiation therapy had a median overall survival of 4.3 months.

Conclusions:

• Radium-223 combination therapy shows limited survival benefit as a standalone treatment for metastatic osteoblastic osteosarcoma.
• The addition of radiation therapy, including SBRT, significantly improved overall survival in patients treated with radium-223.
• Further research is warranted to optimize combination strategies involving radium-223 for osteosarcoma treatment.